Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients - PubMed (original) (raw)
Per Hall, Gert Auer, Judith Bjöhle, Sigrid Klaar, Ulrike Kronenwett, Edison T Liu, Lance Miller, Alexander Ploner, Johanna Smeds, Jonas Bergh, Yudi Pawitan
Affiliations
- PMID: 16846532
- PMCID: PMC1779468
- DOI: 10.1186/bcr1517
Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients
Stefano Calza et al. Breast Cancer Res. 2006.
Abstract
Background: Molecular markers and the rich biological information they contain have great potential for cancer diagnosis, prognostication and therapy prediction. So far, however, they have not superseded routine histopathology and staging criteria, partly because the few studies performed on molecular subtyping have had little validation and limited clinical characterization.
Methods: We obtained gene expression and clinical data for 412 breast cancers obtained from population-based cohorts of patients from Stockholm and Uppsala, Sweden. Using the intrinsic set of approximately 500 genes derived in the Norway/Stanford breast cancer data, we validated the existence of five molecular subtypes--basal-like, ERBB2, luminal A/B and normal-like--and characterized these subtypes extensively with the use of conventional clinical variables.
Results: We found an overall 77.5% concordance between the centroid prediction of the Swedish cohort by using the Norway/Stanford signature and the k-means clustering performed internally within the Swedish cohort. The highest rate of discordant assignments occurred between the luminal A and luminal B subtypes and between the luminal B and ERBB2 subtypes. The subtypes varied significantly in terms of grade (p < 0.001), p53 mutation (p < 0.001) and genomic instability (p = 0.01), but surprisingly there was little difference in lymph-node metastasis (p = 0.31). Furthermore, current users of hormone-replacement therapy were strikingly over-represented in the normal-like subgroup (p < 0.001). Separate analyses of the patients who received endocrine therapy and those who did not receive any adjuvant therapy supported the previous hypothesis that the basal-like subtype responded to adjuvant treatment, whereas the ERBB2 and luminal B subtypes were poor responders.
Conclusion: We found that the intrinsic molecular subtypes of breast cancer are broadly present in a diverse collection of patients from a population-based cohort in Sweden. The intrinsic gene set, originally selected to reveal stable tumor characteristics, was shown to have a strong correlation with progression-related properties such as grade, p53 mutation and genomic instability.
Figures
Figure 1
Logarithmic expression of the ESR1 gene. Boxplots are shown of ESR1 gene expression values (log2 transformed) against subtype in both Swedish cohorts.
Figure 2
Kaplan-Meier relapse-free survival curves. Survival curves are shown for the tumor subtypes in (a) patients with endocrine therapy and (b) patients without any adjuvant therapy. The p value, computed with Cox regression, is for simultaneous comparison of all the curves.
Similar articles
- Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling.
Van Laere SJ, Van den Eynden GG, Van der Auwera I, Vandenberghe M, van Dam P, Van Marck EA, van Golen KL, Vermeulen PB, Dirix LY. Van Laere SJ, et al. Breast Cancer Res Treat. 2006 Feb;95(3):243-55. doi: 10.1007/s10549-005-9015-9. Epub 2005 Oct 27. Breast Cancer Res Treat. 2006. PMID: 16261404 - GATA3 mutations define a unique subtype of luminal-like breast cancer with improved survival.
Jiang YZ, Yu KD, Zuo WJ, Peng WT, Shao ZM. Jiang YZ, et al. Cancer. 2014 May 1;120(9):1329-37. doi: 10.1002/cncr.28566. Epub 2014 Jan 29. Cancer. 2014. PMID: 24477928 - [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM, Zhang BN, Xuan LX, Zhao P. Zhang HM, et al. Zhonghua Zhong Liu Za Zhi. 2009 Jun;31(6):447-51. Zhonghua Zhong Liu Za Zhi. 2009. PMID: 19950556 Chinese. - Nonfamilial breast cancer subtypes.
Ringnér M, Staaf J, Jönsson G. Ringnér M, et al. Methods Mol Biol. 2013;973:279-95. doi: 10.1007/978-1-62703-281-0_18. Methods Mol Biol. 2013. PMID: 23412797 Review. - An integrative hypothesis about the origin and development of sporadic and familial breast cancer subtypes.
Melchor L, Benítez J. Melchor L, et al. Carcinogenesis. 2008 Aug;29(8):1475-82. doi: 10.1093/carcin/bgn157. Epub 2008 Jul 1. Carcinogenesis. 2008. PMID: 18596026 Review.
Cited by
- Carbonic anhydrases reduce the acidity of the tumor microenvironment, promote immune infiltration, decelerate tumor growth, and improve survival in ErbB2/HER2-enriched breast cancer.
Lee S, Toft NJ, Axelsen TV, Espejo MS, Pedersen TM, Mele M, Pedersen HL, Balling E, Johansen T, Burton M, Thomassen M, Vahl P, Christiansen P, Boedtkjer E. Lee S, et al. Breast Cancer Res. 2023 Apr 25;25(1):46. doi: 10.1186/s13058-023-01644-1. Breast Cancer Res. 2023. PMID: 37098526 Free PMC article. - The Multi-Omic Landscape of Primary Breast Tumors and Their Metastases: Expanding the Efficacy of Actionable Therapeutic Targets.
Yang G, Lu T, Weisenberger DJ, Liang G. Yang G, et al. Genes (Basel). 2022 Aug 29;13(9):1555. doi: 10.3390/genes13091555. Genes (Basel). 2022. PMID: 36140723 Free PMC article. Review. - Loss of RPTPγ primes breast tissue for acid extrusion, promotes malignant transformation and results in early tumour recurrence and shortened survival.
Sloth RA, Axelsen TV, Espejo MS, Toft NJ, Voss NCS, Burton M, Thomassen M, Vahl P, Boedtkjer E. Sloth RA, et al. Br J Cancer. 2022 Oct;127(7):1226-1238. doi: 10.1038/s41416-022-01911-6. Epub 2022 Jul 11. Br J Cancer. 2022. PMID: 35821297 Free PMC article. - Elevated EDAR signalling promotes mammary gland tumourigenesis with squamous metaplasia.
Williams R, Jobling S, Sims AH, Mou C, Wilkinson L, Collu GM, Streuli CH, Gilmore AP, Headon DJ, Brennan K. Williams R, et al. Oncogene. 2022 Feb;41(7):1040-1049. doi: 10.1038/s41388-021-01902-6. Epub 2021 Dec 16. Oncogene. 2022. PMID: 34916592 Free PMC article. - RosettaSX: Reliable gene expression signature scoring of cancer models and patients.
Kreis J, Nedić B, Mazur J, Urban M, Schelhorn SE, Grombacher T, Geist F, Brors B, Zühlsdorf M, Staub E. Kreis J, et al. Neoplasia. 2021 Nov;23(11):1069-1077. doi: 10.1016/j.neo.2021.08.005. Epub 2021 Sep 25. Neoplasia. 2021. PMID: 34583245 Free PMC article.
References
- Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869–10874. doi: 10.1073/pnas.191367098. - DOI - PMC - PubMed
- Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P, Han X, Holmberg L, Huang F, Klaar S, et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res. 2005;7:R953–R964. doi: 10.1186/bcr1325. - DOI - PMC - PubMed
- Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA. 2005;102:13550–13555. doi: 10.1073/pnas.0506230102. - DOI - PMC - PubMed
- Egyhazi S, Bjohle J, Skoog L, Huang F, Borg AL, Frostvik Stolt M, Hagerstrom T, Ringborg U, Bergh J. Proteinase K added to the extraction procedure markedly increases RNA yield from primary breast tumors for use in microarray studies. Clin Chem. 2004;50:975–976. doi: 10.1373/clinchem.2003.027102. - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous